Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.
Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Giuseppe D’Alessio(Federico II University Hospital), Carmela Coppola, Gabriele G. Schiattarella(Max Delbrück Center), Gennaro Riccio(Sapienza University of Rome), Nicola Maurea(Cancer Institute (WIA)), Elisa Di Pietro, Grazia Esposito(University of Campania "Luigi Vanvitelli"), R.V. Iaffaioli, Carmine Fedele(American Institutes for Research)
Cited by 4
Related Papers
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Pim-1 regulates cardiomyocyte survival downstream of Akt
|Nature Medicine|2007|239
Microalgae with Immunomodulatory Activities
|Marine Drugs|2019|184